DK0508194T3 - Stabiliserede faktor VIII-præparater - Google Patents

Stabiliserede faktor VIII-præparater

Info

Publication number
DK0508194T3
DK0508194T3 DK92104944T DK92104944T DK0508194T3 DK 0508194 T3 DK0508194 T3 DK 0508194T3 DK 92104944 T DK92104944 T DK 92104944T DK 92104944 T DK92104944 T DK 92104944T DK 0508194 T3 DK0508194 T3 DK 0508194T3
Authority
DK
Denmark
Prior art keywords
factor viii
viii preparations
stabilized factor
stabilized
preparations
Prior art date
Application number
DK92104944T
Other languages
Danish (da)
English (en)
Inventor
Wilfried Freudenberg
Original Assignee
Aventis Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6429102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0508194(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Behring Gmbh filed Critical Aventis Behring Gmbh
Application granted granted Critical
Publication of DK0508194T3 publication Critical patent/DK0508194T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK92104944T 1991-04-09 1992-03-21 Stabiliserede faktor VIII-præparater DK0508194T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4111393A DE4111393A1 (de) 1991-04-09 1991-04-09 Stabilisierte faktor viii-praeparationen

Publications (1)

Publication Number Publication Date
DK0508194T3 true DK0508194T3 (da) 1998-08-24

Family

ID=6429102

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92104944T DK0508194T3 (da) 1991-04-09 1992-03-21 Stabiliserede faktor VIII-præparater

Country Status (12)

Country Link
US (1) US5565427C1 (fr)
EP (1) EP0508194B1 (fr)
JP (2) JP3777467B2 (fr)
KR (1) KR100231398B1 (fr)
AT (1) ATE160942T1 (fr)
AU (1) AU651188B2 (fr)
CA (1) CA2065553C (fr)
DE (2) DE4111393A1 (fr)
DK (1) DK0508194T3 (fr)
ES (1) ES2111579T4 (fr)
GR (1) GR3025873T3 (fr)
IE (1) IE921124A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE198277T1 (de) * 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
SE504074C2 (sv) † 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7244824B2 (en) * 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US7253262B2 (en) * 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
US7560107B2 (en) * 1996-06-26 2009-07-14 Emory University Modified factor VIII
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
RU2244556C2 (ru) 1999-02-22 2005-01-20 Юниверсити Оф Коннектикут Новые не содержащие альбумин составы фактора viii
AU783306B2 (en) 1999-10-04 2005-10-13 Novartis Vaccines And Diagnostics, Inc. Stabilized liquid polypeptide-containing pharmaceutical compositions
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
ATE424215T1 (de) 2003-01-08 2009-03-15 Novartis Vaccines & Diagnostic Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
CA2788505C (fr) * 2003-02-26 2018-09-04 Nektar Therapeutics Conjugues de groupe fonctionnel a facteur polymerique viii
DE10333317A1 (de) † 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
ES2229931B1 (es) * 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
EP1750733B1 (fr) * 2004-05-03 2013-12-11 Emory University Methode d'administration de facteur viii sans domaine b porcin
WO2006071801A2 (fr) * 2004-12-27 2006-07-06 Baxter International Inc Conjugues entre polymeres et facteurs von willbrand
JP5033798B2 (ja) * 2005-07-02 2012-09-26 アレコー・リミテッド タンパク質を含む安定水系
AU2007245190B2 (en) * 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US9441030B2 (en) * 2007-02-23 2016-09-13 Sk Chemicals Co., Ltd. Process for producing and purifying factor VIII and its derivatives
US8187799B2 (en) 2007-04-26 2012-05-29 Bayer Healthcare Llc Stabilization of liquid solutions of recombinant protein for frozen storage
AU2009284113B2 (en) 2008-08-21 2015-05-14 Octapharma Ag Recombinantly produced human factor VIII and IX
CN102143759A (zh) * 2008-09-03 2011-08-03 奥克塔法马股份有限公司 重组制备的因子ⅷ的新型保护组合物
JP5779780B2 (ja) 2008-11-07 2015-09-16 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 第ｖｉｉｉ因子製剤
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
PL3266463T3 (pl) 2009-06-09 2024-03-18 Prolong Pharmaceuticals, LLC Kompozycje hemoglobiny
GB0915480D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
MY188828A (en) * 2010-09-17 2022-01-06 Takeda Pharmaceuticals Co Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph
SG10201509149VA (en) 2010-11-05 2015-12-30 Baxter Int A new variant of antihemophilic factor viii having increased specific activity
JP6060447B2 (ja) 2011-04-08 2017-01-18 バイオ−ラッド ラボラトリーズ インコーポレーティッド 非特異的活性が低下したＳｓｏ７ポリメラーゼコンジュゲート
EP2694670B1 (fr) 2011-04-08 2017-07-19 Bio-Rad Laboratories, Inc. Mélanges de réaction pcr à activité non spécifique réduite
CA2850579A1 (fr) 2011-10-18 2013-04-25 Carsten Horn Procede pour l'amelioration de la stabilite du facteur viii purifie apres la reconstitution
CN102580062B (zh) * 2012-03-09 2017-03-08 中国医学科学院输血研究所 人凝血因子VIII与vWF复合物或人凝血因子VIII制剂的干热处理稳定剂
JP2014138614A (ja) * 2014-04-09 2014-07-31 Sk Chemicals Co Ltd 第ｖｉｉｉ因子とその誘導体の製造及び精製方法
BR112017002090B1 (pt) 2014-08-04 2021-06-01 Csl Limited Composição aquosa de fator viii de coagulação e método de estabilizar uma molécula de fviii
CN114072420B (zh) 2019-07-04 2024-06-11 康诺贝林伦瑙有限公司 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
EP4240757A2 (fr) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Purification de fviii à partir du plasma au moyen d'une adsorption d'oxyde de silicium

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB941019A (en) * 1961-04-27 1963-11-06 Crookes Lab Ltd Improvements in and relating to the stability of anti-haemophilic globulin (factor viii)
EP0035204B2 (fr) * 1980-03-05 1991-05-22 Miles Inc. Compositions pasteurisées de protéines thérapeutiquement actives
DE3481109D1 (de) * 1983-05-09 1990-03-01 Novo Nordisk As Antihaemophilie-faktor-viii-konzentrat und dessen herstellungsverfahren.
US4743680A (en) * 1985-02-01 1988-05-10 New York University Method for purifying antihemophilic factor
CA1329760C (fr) * 1987-10-29 1994-05-24 Ted C. K. Lee Formulation de plasma et de proteines recombinantes dans des milieux a grande force ionique
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
FR2644064B1 (fr) * 1989-02-17 1994-05-27 Aquitaine Dev Transf Sanguine Procede de fabrication du facteur antihemophilique fviiic ayant une tres haute purete et facteur antihemophilique fviiic ainsi obtenu, ainsi que composition pharmaceutique le contenant
US5110907A (en) * 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
DE3926034C3 (de) * 1989-08-07 1996-11-21 Behringwerke Ag Verfahren zur Herstellung eines stabilen Faktors VIII
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
IT1248723B (it) * 1990-06-12 1995-01-26 Scalvo S P A Processo per la purificazione del fattore viii e fattore viii ottenuto con tale processo
JP4021982B2 (ja) * 1998-03-03 2007-12-12 信越化学工業株式会社 ハイブリッド型ウイグラ

Also Published As

Publication number Publication date
JPH0597702A (ja) 1993-04-20
ES2111579T3 (es) 1998-03-16
AU1470292A (en) 1992-10-15
KR920019371A (ko) 1992-11-19
JP3809501B2 (ja) 2006-08-16
GR3025873T3 (en) 1998-04-30
AU651188B2 (en) 1994-07-14
DE4111393A1 (de) 1992-10-15
EP0508194A1 (fr) 1992-10-14
DE59209051D1 (de) 1998-01-22
ES2111579T4 (es) 2011-12-29
EP0508194B1 (fr) 1997-12-10
JP3777467B2 (ja) 2006-05-24
JP2002097199A (ja) 2002-04-02
IE921124A1 (en) 1992-10-21
CA2065553C (fr) 2003-06-10
US5565427C1 (en) 2002-07-23
US5565427A (en) 1996-10-15
KR100231398B1 (ko) 1999-11-15
CA2065553A1 (fr) 1992-10-10
ATE160942T1 (de) 1997-12-15

Similar Documents

Publication Publication Date Title
US5565427C1 (en) Stabilized factor viii preparations
DE69002795D1 (de) Stabilisierte, den epidermalen wachstumsfaktor enthaltende mittel.
ATE204532T1 (de) Flasche
DE69130020D1 (de) Stabilisierte, retinoide enthaltende hautpflegepräparate
DE68906293D1 (de) Zufuhr von kohlendioxid.
DE68924560D1 (de) Quergerippter Rasierkopf.
DE68900210D1 (de) Pyranobenzoxadiazolderivate, herstellung, verwendung und diese enthaltende zubereitungen.
EG18865A (en) Phenoxypenythioureas, phenoxyphenylisothiourreas and phenoxyphenylcarbodiimides and use thereof for controlling pests.
IT1226152B (it) Ago trequarti per laparoscopia.
DE69231883D1 (de) 4-(1,1-Dialkoxycarbonyl-Alkyl)Azetidin-2-on-Derivate zur Herstellung von 4-(1-Carboxy-Alkyl)Azetidin-2-on-Derivaten
DE59200298D1 (de) Verfahren zur Herstellung von 2,4-Dichlorfluorbenzol.
DE68905657D1 (de) Verwendung von arginin-aspartat zur herstellung eines arzneimittels zur behandlung gewisser gedaechtnisstoerungen.
DE68905273D1 (de) Vorrichtung zur herstellung von yoghurt.
DE69008834D1 (de) Chirurgischer Faden.
EP0401262A4 (en) 24r-scymnol, and preparation and use thereof
DE69200728D1 (de) Vorrichtung zur Herstellung von Chenille.
ES1007248Y (es) Tobera antigoteo.
FI894455A (fi) 1,4-dihydropyridinderivat.
FI893366A (fi) 4-piperidylmetyl-2,3-dihydro-1h -isoindol- och 2,3,4,5-tetrahydro-1h-bensasepinderivat, deras framstaellning och terapeutiska anvaendning.
DE59203827D1 (de) Verfahren zur Herstellung von 2,2-Bis-hydroxymethyl-butandiol-(1,4).
DE69022560D1 (de) N,N'-hydrocarbylen-bis-(N-hals)-substituierte Amidhydrazide.
IT8921236A0 (it) Procedimento per produrre pezzi stampati e dispositivo per l'esecuzione del procedimento.
DE59203617D1 (de) Verfahren zur Herstellung von 2,4-Dichlor-5-fluorbenzonitril.
DE3878988D1 (de) 1,2-di(4-isobutylphenyl)aethylen, dessen herstellung und verwendung als zwischenprodukt.
ITTO930116A0 (it) Procedimento per preparare uan soluzione contentente semitrichinoyl, con proprieta' terapeutiche.